Funding or Fundraising-Announcements

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies.

By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as a commercialization agent for its members and researchers.

Earlier this year, the Networks of Centres of Excellence of Canada awarded MI $14.95 million to continue its mandate as a Centre of Excellence for Commercialization and Research (CECR), matched by $25 million from membership fees and private sector investments.

So what does that success mean for MI’s ability to serve the needs of academic entrepreneurs based in Toronto?

Minuum closes on $60,000 crowdfunded stretch goal to build wearable development kit

Minuum's one-line QWERTY keyboard on a touch device — Minuum’s one-line QWERTY keyboard on a touch device leaves more screen space for content.

Whirlscape Inc.‘s Minuum keyboard has enjoyed the kind of launch that start-up founders dream about yet few achieve.

UPDATE: Whirlscape’s Minuum Project has now cleared its $60,000 fundraising target. Mobile Syrup wrote a follow-up article on the campaign with details about the Wearable Development Kit. Their technology also got a second spot on CTV News‘s Tech Tuesday report and was featured on Global TV’s The Morning Show.

The little keyboard for big fingers, which launched an Indiegogo campaign a week ago today to support the launch of its Android keyboard app and a wearable development kit, is currently less than $4,000 from its crowd-funded stretch goal of $60,000.

The company was featured on CTV News on Mar. 24, 2013. The CTV video story and photos of CEO Will Walmsley and CTO Xavier Snelgrove are available on CTV’s website.

Minuum to end battle between mobile screen space and virtual keyboards

Start-up launches Indiegogo campaign to change future of mobile typing

Minuum keyboard on an Android phone — The Minuum keyboard: “the little keyboard for big fingers.” Designed by Whirlscape Inc., this one-dimensional, tiny keyboard frees up mobile screen space while allowing fast, accurate typing.

TORONTO, March 18, 2013 — Whirlscape Inc., a Canadian tech start-up, has developed Minuum, “the little keyboard for big fingers.”

Updated: The company has now cleared its $60,000 stretch goal to build a wearable development kit. Read the Mobile Syrup follow-up story.

Minuum’s crowdfunding campaign was covered by the Financial Post, CBC News, CTV News, the Toronto Star and Metro Morning (radio interview). They also did a second spot on CTV News‘s Tech Tuesday report and were featured on Global TV’s The Morning Show.

The story was also picked up by Fast Company, Mashable, CNET, TechCrunch, TechCrunch Japan, TechVibes, Huffington Post, Toronto Standard, BlogTO and Mobile Syrup.

Minuum is a tiny, one-dimensional keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm corrects highly imprecise typing.

This algorithm, based on the touchscreen and wearable device research of company founders, Will Walmsley (researcher) and Khai Truong (associate professor) at the University of Toronto, configures the difference between what you type and what you mean, in real time, getting it right even if you miss every single letter.

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.

Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.

XLV’s solution has the potential to provide image quality that equals or surpasses that which is currently in use, making images easy to analyze, manipulate and transfer much like digital photographs. It will also substantially decrease the cost of digital mammography machines.

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result.

The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada’s Business Innovation Summit 2013 in Toronto this morning.

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

February 6, 2013
Susanne Staer
Awards

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions

TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?

MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for its 16 member institutions.

This announcement was covered by TechVibes, Yonge Street Media and CanTech Letter.

The Networks of Centres of Excellence (NCE) has recognized the increasing strength of this novel partnership by awarding MI $14.95 million in funding through the Centres of Excellence for Commercialization and Research (CECR) program.

University of Toronto Early-Stage Technology Program (UTEST) opens applications for second start-up company cohort

January 30, 2013
Susanne Staer
CoursePeer

Students, faculty and recent alumni with software ideas must apply by Feb. 22

Got a killer software-based idea? Are you passionate about turning that idea into a start-up company?

If you’re a current student, faculty member or recent graduate of the University of Toronto, consider applying to the University of Toronto Early-Stage Technology (UTEST) program.

Applications are now closed. Stay tuned for the third UTEST application call.

Created as a pilot in 2012 to help the U of T community bring their software-based ideas to market, UTEST is part of a growing ecosystem of incubators and commercialization support services.

UTEST accepts companies in the very earliest stages of idea generation— before they’re ready for traditional incubators — and awards each company up to $30,000 in start-up funds.

It also provides nascent software companies with office space in the MaRS Discovery District, mentoring and business strategy support.

“From a results standpoint, we couldn’t be more satisfied with first cohort of companies,” says Kurtis Scissons, co-director of UTEST at U of T. “In six months, they secured over $650,000 in follow-on funding. Each has filed solid patent protection and some are already gaining customer traction. They have also collectively created 21 highly-skilled jobs (HQPs).”

Update May 2013: Those figures now stand at $1.2 million and 29 jobs; most of the companies have secured customers.

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) – ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.

This story was covered in Yonge Street Media on January 30, 2013.

ScarX, a topical medication, emerged from Dr. Benjamin Alman‘s research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.

Benjamin Alman, founder of ScarX Therapeutics. — **Dr. Benjamin Alman**, founder of ScarX Therapeutics. Photo courtesy of The Hospital for Sick Children.

Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription therapeutic exists to reduce post-surgical scarring. Given this critical need for its technology, ScarX Therapeutics believes sales of the ScarX product could potentially reach into the billions of dollars.

“ScarX is a true game-changer when it comes to reducing the scarring associated with many surgeries,” said Dr. Tom Corr, president and CEO of Ontario Centres of Excellence. “Through our Market Readiness program, OCE is pleased to be supporting both the commercialization of this revolutionary research-based product and Ontario’s economy.”

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients.”

Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR’s Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li’s proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.

U of T, MaRS Innovation Collaborate to Launch Incubator for Student Software Companies

October 1, 2012
Susanne Staer
CoursePeer

Hadi Aladdin (left) and Marwan Aladdin, U of T graduates and the founders of CoursePeer. — **Hadi Aladdin** (left) and **Marwan Aladdin**, U of T graduates and the founders of **CoursePeer**, one of six UTEST companies.

TORONTO, ON – A new program that provides nascent software companies with start-up funds, work space, mentoring and business strategy support, was launched today by the University of Toronto and commercialization partner MaRS Innovation, with support from the MaRS Discovery District.

TechVibes has a profile page for UTEST and covered CoursePeer as part of their students start-ups series.

The new program, called University of Toronto Early Stage Technology (UTEST), is part of a growing ecosystem of incubators and commercialization support services at U of T, including the newly-launched Banting and Best Institute. UTEST is unique among campus incubators in that its companies receive start-up funds—$30,000 each in this inaugural year—and because it accepts companies in the very earliest stages of idea generation, before they’re ready for traditional incubators.

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Minuum closes on $60,000 crowdfunded stretch goal to build wearable development kit

Minuum to end battle between mobile screen space and virtual keyboards

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

University of Toronto Early-Stage Technology Program (UTEST) opens applications for second start-up company cohort

Students, faculty and recent alumni with software ideas must apply by Feb. 22

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

U of T, MaRS Innovation Collaborate to Launch Incubator for Student Software Companies

Quick Links

Contact Us